Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | EIF4E | P06730 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MYC | P01106 | 1/20 | 0.30 |
| ▸ | WDR5 | P61964 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19626558 | 0.86 | MAPT (0.45) | MAPTALDH1A1SMN1; SMN2L3MBTL1HTT | |
| SCHEMBL19625334 | 0.78 | EIF4E (0.47) | MAPTALDH1A1EIF4ETP53TDP1 | |
| SCHEMBL19625522 | 0.76 | GRM5 (0.34) | MAPTALDH1A1TDP1KMT2A | |
| SCHEMBL19625380 | 0.75 | MAPK1 (0.37) | MAPTALDH1A1SMN1; SMN2EIF4EL3MBTL1 | |
| SCHEMBL19625337 | 0.75 | KMT2A (0.42) | MAPTALDH1A1EIF4EL3MBTL1KMT2A | |
| SCHEMBL19625333 | 0.75 | KMT2A (0.43) | MAPTALDH1A1TP53TDP1HTT | |
| SCHEMBL19625343 | 0.75 | CDC25A (0.41) | MAPTALDH1A1EIF4E | |
| SCHEMBL17625937 | 0.74 | SMN1; SMN2 (0.32) | MAPTSMN1; SMN2HPGDTDP1L3MBTL1 | |
| SCHEMBL19625500 | 0.71 | KDM4E (0.43) | MAPTALDH1A1HPGDTDP1HTT | |
| SCHEMBL19625371 | 0.71 | MAPT (0.51) | MAPTALDH1A1SMN1; SMN2HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | WNT1, WNT3A, CTNNB1 | MAPT 4783/4885ALDH1A1 1166/4885SMN1; SMN2 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.